Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Repatha
Repatha
Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too
Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too
Endpoints
Amgen
patents
Sanofi
Regeneron
Praluent
Repatha
Merck
Flag link:
ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha
ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha
Fierce Pharma
ESC
Amgen
Repatha
Sanofi
Regeneron
Praluent
cholesterol
Flag link:
ACC: Amgen's Repatha cuts cholesterol in rarely studied HIV patients
ACC: Amgen's Repatha cuts cholesterol in rarely studied HIV patients
Fierce Pharma
ACC
Repatha
HIV
clinical trials
Amgen
Flag link:
Two Big Drug Flops Show How Health-Care Economics Have Changed
Two Big Drug Flops Show How Health-Care Economics Have Changed
Bloomberg
drug pricing
Sanofi
Amgen
Praluent
Repatha
Flag link:
AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients
AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients
Fierce Pharma
AHA
Amgen
Repatha
PCSK9 inhibitor
heart attacks
Flag link:
Amgen slashes price tag on cholesterol medicine Repatha by 60% for 2020
Amgen slashes price tag on cholesterol medicine Repatha by 60% for 2020
Yahoo/Reuters
Amgen
drug pricing
Repatha
Flag link:
MedCo's PCSK9 challenger steals the show at ESC with winning data
MedCo's PCSK9 challenger steals the show at ESC with winning data
Fierce Pharma
Medicines Company
ESC
PCSK9 inhibitors
inclisiran
Repatha
Praluent
European Society of Cardiology
Flag link:
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Fierce Pharma
Sanofi
Regeneron
Amgen
PCSK9 inhibitors
patents
Praluent
Repatha
Flag link:
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Fierce Pharma
Amgen
Regeneron
Sanofi
Praluent
Repatha
Medicines Company
PCSK9 inhibitors
inclisiran
Flag link:
German court blocks sale of Sanofi, Regeneron cholesterol drug
German court blocks sale of Sanofi, Regeneron cholesterol drug
Biopharma Dive
patents
Amgen
Sanofi
Regeneron
Germany
Praluent
Repatha
Flag link:
Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
Investors Business Daily
Amgen
Repatha
clinical trials
Flag link:
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Biopharma Dive
Regeneron
Sanofi
Amgen
Praluent
Repatha
drug pricing
PCSK9 inhibitors
Flag link:
Amgen touts lowered prices for Repatha delivery devices
Amgen touts lowered prices for Repatha delivery devices
Drug Delivery Business News
Amgen
drug delivery
Repatha
Flag link:
7 drugs that raised eyebrows in Q3
7 drugs that raised eyebrows in Q3
Biopharma Dive
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
Flag link:
In Unprecedented Move, Amgen Cuts Price Of Cholesterol Drug Repatha By 60%
In Unprecedented Move, Amgen Cuts Price Of Cholesterol Drug Repatha By 60%
Forbes
Amgen
Repatha
drug pricing
Flag link:
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Fierce Pharma
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
Supreme Court
Praluent
Repatha
Flag link:
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
NASDAQ.com
Amgen
Repatha
type 2 diabetes
diabetes
hypercholesterolemia
ADA
Flag link:
Are These Disappointing Drugs Back on Track to Billions?
Are These Disappointing Drugs Back on Track to Billions?
Motley Fool
PCSK9 inhibitors
Sanofi
Regeneron
Amgen
Praluent
Repatha
Flag link:
Amgen focuses on migraine launch as growth remains slow
Amgen focuses on migraine launch as growth remains slow
Biopharma Dive
Amgen
earnings
Repatha
Kyprolis
Prolia
Xgeva
Flag link:
Is Amgen’s Outcomes-Based Pricing Model for Repatha Benefiting Patients and Payers?
Is Amgen’s Outcomes-Based Pricing Model for Repatha Benefiting Patients and Payers?
Xtalks
Amgen
Repatha
outcome-based pricing
drug pricing
patients
Flag link:
Pages
1
2
3
4
5
6
7
8
next ›
last »